Subarachnoid Hemorrhage, Aneurysmal Clinical Trial
Official title:
Determination of Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration - a Descriptive Pharmacokinetic/Pharmacodynamics Study
Nimodipine reduces the risk of poor outcome and delayed cerebral ischemia in patients suffering aneurysmal subarachnoid haemorrhage (SAH), but its mode of action is unknown. Its beneficial effect is assumed to be due its neuroprotective effects by reducing intracellular calcium and thereby cellular apoptosis, but higher concentrations might induce marked systemic hypotension, thereby inducing cerebral ischemia. Since several dosing regimes and routes of administration with inconclusive superiority exist and since the target site concentration of nimodipine - the unbound drug concentrations beyond the blood-brain barrier - is still not known, it is reasonable to measure nimodipine concentrations within the blood, cerebrospinal fluid (CSF) and interstitial brain tissue following oral, intra-venous and intra-arterial administration and correlate intra-arterial nimodipine administration to measures of cerebral metabolism and oxygenation. Therefore, the investigators propose to investigate in 30 patients suffering severe aneurysmal SAH and requiring cerebral microdialysis for cerebral neurochemical monitoring: - the ability of nimodipine to penetrate into the brain of neurointensive care patients by comparing exposure in brain, CSF and plasma, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial) and dosing intra-venously (0.5 - 2mg/h) - the impact of orally, intra-venously, and intra-arterially delivered nimodipine on cerebral metabolism, i.e. lactate/pyruvate ratio, pbtO2 and transcranial doppler flow velocities - the effect of oral and intra-venous nimodipine on systemic hemodynamic and cardiac parameters, using continuous Pulse Contour Cardiac Output (PiCCO) monitoring - the penetration properties of ethanol - as an excipient of nimodipine infusion - into the brain by comparing exposure in brain, CSF and plasma and quantifying the neuronal exposure to alcohol dependent on blood levels
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032533 -
Remote Ischemic Conditioning in Aneurysmal SAH
|
N/A | |
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Recruiting |
NCT06006975 -
Early Warning of Delayed Cerebral Ischemia
|
||
Terminated |
NCT02893826 -
Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH
|
Phase 1 | |
Unknown status |
NCT01567449 -
Risk Factors for Aneurysm Rebleeding
|
N/A | |
Recruiting |
NCT05095857 -
The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
|
Phase 4 | |
Not yet recruiting |
NCT04512859 -
Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT05103566 -
Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT04415736 -
Artificial Intelligence in Subarachnoid Hemorrhage
|
||
Recruiting |
NCT05925478 -
Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage
|
Early Phase 1 | |
Recruiting |
NCT02995928 -
Trial of Prophylactic Decompressive Craniectomy for Poor-grade Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT04945603 -
Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group
|
||
Active, not recruiting |
NCT06239142 -
Understanding Mental Fatigue After Subarachnoid Hemorrhage
|
||
Completed |
NCT03318783 -
Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
|
Phase 1/Phase 2 | |
Terminated |
NCT05686265 -
Cerebral Nitrosative/Oxidative Stress in Aneurysmal Subarachnoid Haemorrhage
|
||
Not yet recruiting |
NCT06057155 -
Intracranial Pressure and Optic Nerve Sheath Diameter With CLOSED Bundle
|
||
Not yet recruiting |
NCT06359782 -
Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
|
Phase 2 | |
Completed |
NCT03115905 -
A Registry Study for Emergency Medical Service of Aneurysmal Subarachnoid Hemorrhage in China
|